Guilty as CHARGED: p53's expanding role in disease

Area of Science:

• Molecular Biology
• Developmental Biology
• Genetics

Background:

• Unrestrained p53 activity due to loss of negative regulators (Mdm2, Mdmx) leads to early embryonic lethality.
• The tumor suppressor p53 plays a critical role in development and disease.
• CHARGE syndrome is typically associated with mutations in the CHD7 chromatin remodeler.

Purpose of the Study:

• To investigate the developmental consequences of co-expressing wild-type p53 with a transcriptionally inactive p53 variant.
• To explore the role of p53 in CHARGE syndrome phenotypes.
• To understand p53's broader role in non-cancerous diseases.

Main Methods:

• Generating and analyzing embryos with specific p53 mutations (p53(L25Q,W26S,F53Q,F54S)).
• Molecular analyses to assess p53 activation and downstream effects.
• Investigating the interplay between activated p53 and CHD7 deficiency.

Main Results:

• Co-expression of wild-type p53 and the transcriptionally dead p53 variant caused later embryonic lethality with CHARGE-like phenotypes.
• Wild-type p53 was inappropriately activated in these embryos, leading to cell-cycle arrest or apoptosis.
• Activated p53 was found to contribute to phenotypes associated with CHD7 deficiency.

Conclusions:

• Inappropriate p53 activation during development can cause specific syndromes like CHARGE.
• Activated p53 exacerbates phenotypes resulting from CHD7 deficiency.
• This research offers new insights into CHARGE syndrome and p53's role beyond cancer.